- Home
- GLO vs ATAI Comparison
GLO vs ATAI Comparison
Compare GLO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLO
- ATAI
- Stock Information
- Founded
- GLO 2006
- ATAI 2018
- Country
- GLO United States
- ATAI Netherlands
- Employees
- GLO N/A
- ATAI N/A
- Industry
- GLO Finance/Investors Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GLO Finance
- ATAI Health Care
- Exchange
- GLO Nasdaq
- ATAI Nasdaq
- Market Cap
- GLO 245.9M
- ATAI 1.1B
- IPO Year
- GLO N/A
- ATAI 2021
- Fundamental
- Price
- GLO $5.76
- ATAI $5.85
- Analyst Decision
- GLO
- ATAI Strong Buy
- Analyst Count
- GLO 0
- ATAI 5
- Target Price
- GLO N/A
- ATAI $14.00
- AVG Volume (30 Days)
- GLO 170.5K
- ATAI 7.0M
- Earning Date
- GLO 01-01-0001
- ATAI 11-12-2025
- Dividend Yield
- GLO 11.38%
- ATAI N/A
- EPS Growth
- GLO N/A
- ATAI N/A
- EPS
- GLO N/A
- ATAI N/A
- Revenue
- GLO N/A
- ATAI $2,309,000.00
- Revenue This Year
- GLO N/A
- ATAI $736.04
- Revenue Next Year
- GLO N/A
- ATAI N/A
- P/E Ratio
- GLO N/A
- ATAI N/A
- Revenue Growth
- GLO N/A
- ATAI 510.85
- 52 Week Low
- GLO $4.08
- ATAI $1.04
- 52 Week High
- GLO $5.18
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- GLO 57.02
- ATAI 55.30
- Support Level
- GLO $5.62
- ATAI $5.50
- Resistance Level
- GLO $5.71
- ATAI $6.73
- Average True Range (ATR)
- GLO 0.08
- ATAI 0.50
- MACD
- GLO -0.00
- ATAI -0.04
- Stochastic Oscillator
- GLO 82.05
- ATAI 44.14
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.